Join the largest connected site network

in the US for free

As a member of our site network community, you maintain "Full Ownership" of your data and only the fully de-identified data is added to the network.iPatientAxis has partnered with the top CRO, Biotech and Pharma companies to streamline an objective approach to site selection.

Being part of the network allows your site to be automatically and immediately identified for a clinical trial where you actually have patients that match the criteria. This ability greatly increases your sites visibility and consideration for trials that might not have been opportunities without iPatientAxis. Our partnership will significantly reduce the need for business development, limit staff time waste and lessen unreimburseable tasks driven by subjective and manual processes.

to be added

Retain Full Ownership of and Access to Patient Data

All data is controlled by the contributing site,under the strictest of cloud-based security standards and de-identification algorithms.

Fully Compliant with all data privacy regulations, both US(Safe Harbor) & internationally.

to be added

Attract and Field More Clinical Trial Opportunities

Participation in the Connected Site Network allows sites to be pre-selected for trials they are demonstrated to have patients.

Ensure Appropriate staff resourcing based on documented time savings and predictable turnaround times.

to be added

Automate and Streamline Internal Workflows

Enjoy access to reports designed expressly for sites, with additional features that include centralized feasibility, tasking and KPI reporting.

Automated identification results in robustly-matched cohorts and ultimately, better enrollment.

to be added

EMR Agnostic

Our integration experts have integrated with over 100 different EMRs throughtout our 6,000 site network. We can seamlessly connect your site at no cost, allowing your team greater visibility into your database, maximizing your EMR investment, by automatically deriving knowledge and positive exposure to additional clinical trials, all while fully maintaining control and ownership of your data.